Posted by Michael Wonder on 04 Jul 2019
Karyopharm Therapeutics prices blood cancer treatment after FDA approval
4 July 2019 - Karyopharm Therapeutics has set a list-price for its blood cancer treatment Xpovio at $22,000 per month, following accelerated approval from the U.S. FDA.
Karyopharm said it expects Xpovio to become commercially available in the United States by July 10.
The list price is for all four available dosing packages.
